XTRA:BNN

Stock Analysis Report

B.R.A.I.N. Biotechnology Research and Information Network

Executive Summary

B.R.A.I.N. Biotechnology Research and Information Network AG researches, develops, produces, and markets enzymes, biocatalysts, microorganisms, and bioactive natural substances for chemical and consumer goods industries in Germany, the United States, France, and the United Kingdom.


Snowflake Analysis

High growth potential with adequate balance sheet.


Similar Companies

Share Price & News

How has B.R.A.I.N. Biotechnology Research and Information Network's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: BNN's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

7.5%

BNN

2.0%

DE Chemicals

2.2%

DE Market


1 Year Return

-38.5%

BNN

-33.0%

DE Chemicals

-17.2%

DE Market

Return vs Industry: BNN underperformed the German Chemicals industry which returned -33% over the past year.

Return vs Market: BNN underperformed the German Market which returned -17.2% over the past year.


Shareholder returns

BNNIndustryMarket
7 Day7.5%2.0%2.2%
30 Day-27.4%-16.7%-15.7%
90 Day-40.3%-32.7%-24.0%
1 Year-38.5%-38.5%-30.4%-33.0%-14.9%-17.2%
3 Year-62.4%-62.4%-41.5%-47.0%-16.4%-23.3%
5 Yearn/a-36.4%-46.1%-16.5%-27.8%

Price Volatility Vs. Market

How volatile is B.R.A.I.N. Biotechnology Research and Information Network's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is B.R.A.I.N. Biotechnology Research and Information Network undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: BNN (€6.45) is trading below our estimate of fair value (€24.18)

Significantly Below Fair Value: BNN is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: BNN is unprofitable, so we can't compare its PE Ratio to the Chemicals industry average.

PE vs Market: BNN is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BNN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: BNN is overvalued based on its PB Ratio (7.6x) compared to the DE Chemicals industry average (1.2x).


Next Steps

Future Growth

How is B.R.A.I.N. Biotechnology Research and Information Network forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

69.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BNN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.4%).

Earnings vs Market: BNN is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: BNN's is expected to become profitable in the next 3 years.

Revenue vs Market: BNN's revenue (13.8% per year) is forecast to grow faster than the German market (4.1% per year).

High Growth Revenue: BNN's revenue (13.8% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: BNN's Return on Equity is forecast to be very high in 3 years time (132.3%).


Next Steps

Past Performance

How has B.R.A.I.N. Biotechnology Research and Information Network performed over the past 5 years?

2.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: BNN is currently unprofitable.

Growing Profit Margin: BNN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: BNN is unprofitable, but has reduced losses over the past 5 years at a rate of 2.2% per year.

Accelerating Growth: Unable to compare BNN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BNN is unprofitable, making it difficult to compare its past year earnings growth to the Chemicals industry (-8.9%).


Return on Equity

High ROE: BNN has a negative Return on Equity (-75.3%), as it is currently unprofitable.


Next Steps

Financial Health

How is B.R.A.I.N. Biotechnology Research and Information Network's financial position?


Financial Position Analysis

Short Term Liabilities: BNN's short term assets (€28.1M) exceed its short term liabilities (€14.5M).

Long Term Liabilities: BNN's short term assets (€28.1M) do not cover its long term liabilities (€40.7M).


Debt to Equity History and Analysis

Debt Level: BNN is debt free.

Reducing Debt: BNN has no debt compared to 5 years ago when its debt to equity ratio was 51.7%.


Balance Sheet

Inventory Level: BNN has a high level of physical assets or inventory.

Debt Coverage by Assets: BNN's debt is not covered by short term assets (assets are -20.8x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BNN has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if BNN has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is B.R.A.I.N. Biotechnology Research and Information Network's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate BNN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate BNN's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BNN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BNN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BNN's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.3yrs

Average management tenure


CEO

Aryan Moelker

no data

Tenure

Mr. Adriaan Moelker, also known as Aryan, has been Chairman of the Management Board and Chief Executive Officer of B.R.A.I.N. Biotechnology Research and Information Network AG since February 1, 2020. Mr. M ...


Leadership Team

NamePositionTenureCompensationOwnership
Manfred Bender
CFO & Member of Management Board1.17yrs€380.60kno data
Ludger Roedder
Chief Business Officer & Member of Management Board1.42yrs€389.60kno data
Jürgen Eck
Consultant0.25yr€468.00kno data
Adriaan Moelker
Chairman of the Management Board & CEOno datano datano data
Ulrich Putsch
Co-Founderno datano datano data
Martin Langer
Executive VP & Head Industrial BioSolutions Business Unitno datano datano data
Guido Meurer
Executive VP & Head of Technology Unit - Producer Strain Developmentno datano datano data
Ute Dechert
Head of Organisation & Processes Unitno datano datano data
Michael Krohn
Executive VP and Head of Research & Developmentno datano datano data
Lukas Linnig
Unit Head of Finance & Controlling2.17yrsno datano data

1.3yrs

Average Tenure

55yo

Average Age

Experienced Management: BNN's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Georg Kellinghusen
Independent Chairman of the Supervisory Board1yr€70.00kno data
Michael Majerus
Independent Member of Supervisory Board1yr€27.00kno data
Bernhard Hauer
Member of Supervisory Board1yr€14.00kno data
Anna Eichhorn
Deputy Chairwoman of the Supervisory Board0.17yr€41.00kno data

1.0yrs

Average Tenure

61yo

Average Age

Experienced Board: BNN's board of directors are not considered experienced ( 1 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

B.R.A.I.N. Biotechnology Research and Information Network AG's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: B.R.A.I.N. Biotechnology Research and Information Network AG
  • Ticker: BNN
  • Exchange: XTRA
  • Founded: 1993
  • Industry: Specialty Chemicals
  • Sector: Materials
  • Market Cap: €116.460m
  • Shares outstanding: 18.06m
  • Website: https://www.brain-biotech.de

Number of Employees


Location

  • B.R.A.I.N. Biotechnology Research and Information Network AG
  • Darmstadter Strasse 34-36
  • Zwingenberg
  • Hessen
  • 64673
  • Germany

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BNNDB (Deutsche Boerse AG)YesOrdinary SharesDEEURJan 2016
BNNXTRA (XETRA Trading Platform)YesOrdinary SharesDEEURJan 2016
0RFILSE (London Stock Exchange)YesOrdinary SharesGBEURJan 2016
BNNDBATS-CHIXE (BATS 'Chi-X Europe')YesOrdinary SharesGBEURJan 2016

Biography

B.R.A.I.N. Biotechnology Research and Information Network AG researches, develops, produces, and markets enzymes, biocatalysts, microorganisms, and bioactive natural substances for chemical and consumer goods industries in Germany, the United States, France, and the United Kingdom. It operates through BioScience and BioIndustrial segments. The company identifies and develops bioactive natural compounds, including sugar substitutes and taste modulators, and natural-source substances for product development in the food, animal feed, skincare, cosmetics, and chemical industries, as well as to stabilize paints, lacquers, and other household products; It also identifies and develops optimized enzymes and biocatalysts for the production of food and beverages, and wound care preparations and lubricants, as well as for starch processing of bioethanol production; and microorganisms as the functional biomass for optimized industrial production processes, recycling of climate gas CO2 as an industrial raw material for bioplastics, and extraction of precious and rare earth metals. The company has a strategic partnership with AnalytiCon Discovery GmbH and Roquette to develop natural sweeteners and sweet taste enhancers. B.R.A.I.N. Biotechnology Research and Information Network AG was founded in 1993 and is headquartered in Zwingenberg, Germany. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/03/31 23:26
End of Day Share Price2020/03/31 00:00
Earnings2019/12/31
Annual Earnings2019/09/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.